* Biotech files for $100 mln IPO
* Will use proceeds for working capital, general purposes
(Adds detail on shareholders, background)
NEW YORK Dec 28 U.S. biotechnology company
Codexis Inc filed for an initial public offering of up to $100
million on Monday.
The company provides enzymes and microbes that make
industrial processes cleaner and faster.
Its pharmaceutical products are used by drugmakers including
Merck & Co Inc (MRK.N), Pfizer Inc (PFE.N) and Dr Reddy's
Laboratories Ltd (REDY.BO).
Codexis said it is also working with Royal Dutch Shell
(RDSa.L) on biofuel products, and is pursuing the carbon
management, water treatment and chemical industries.
Codexis is one of a passel of green technology companies
expected to go public this year.
California solar company Solyndra earlier this month filed
with the U.S. Securities and Exchange Commission for an IPO of
up to $300 million.
Smart grid networking company Silver Spring Networks and
electric car maker Tesla have also been eyed as likely
candidates for IPOs.
Codexis reported product revenue of $13.4 million in the
nine months ended Sept. 30, up from $10.8 million in the same
period a year ago. The company reported a net loss of $15.1
million, narrower than its $38.8 million loss from a year ago.
Shareholders include Maxygen Inc, Biomedical Sciences
Investment Fund, and funds associated with Shell, CMEA
Ventures, FirstMark Capital and CTTV Investments.
The Redwood City, California-based company plans to list on
the Nasdaq under the symbol "CDXS." It said it will use
proceeds from the offering for working capital and general
Credit Suisse and Goldman Sachs are set to lead the
underwriting syndicate on the deal.
(Reporting by Clare Baldwin; Editing by Steve Orlofsky)